Bayer Cipro XR
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approves Bayer's Cipro XR (ciprofloxacin extended-release) Dec. 13 for once-daily treatment of uncomplicated urinary tract infections (UTIs), giving the firm nearly one year to establish the extended-release product before Cipro faces patent expiration in December 2003. The indication was supported by an 891-patient study showing the safety and efficacy of 500 mg Cipro XR to be comparable to conventional 250 mg twice-daily Cipro. An application for complicated UTIs was submitted Oct. 29 (Pharmaceutical Approvals Monthly, Dec. 1, 2002, p. 20). Bayer is highlighting the convenience of the once-daily formulatio
You may also be interested in...
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?
“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: